GlassScriptPhysician profile
Melissa M Chan
NPI 1417912031
$9,904.97
in general payments reported to CMS, 2019-2025
27 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $1,120 · 2021: $1,771 · 2022: $1,046 · 2023: $1,201 · 2024: $2,048 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,599 · Education: $26.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.57 |
| Education | $26.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,862.10 | 2019-2025 | Qulipta, Vraylar, Rinvoq |
| Astrazeneca Pharmaceuticals LP | $2,169.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $1,403.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $614.13 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.94 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $366.67 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Angiodynamics, INC. | $260.48 | 2024 | Angiodynamics, Nanoknife |
| Pfizer INC. | $222.59 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $191.26 | 2020-2021 | |
| Medtronic, INC. | $188.90 | 2025 | Symplicity G3 |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Alcon Vision LLC | $147.33 | 2025 | Hydrus Microstent |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $112.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $102.77 | 2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $93.71 | 2023 | Krystexxa |
| Allergan, INC. | $58.20 | 2019-2020 | |
| Seqirus USA INC | $34.13 | 2022-2025 | Flucelvax |
| Mannkind Corporation | $32.96 | 2020 | |
| Merz North America, INC. | $29.18 | 2023 | Xeomin |
| Kowa Pharmaceuticals America, INC. | $28.05 | 2020 | |
| Lilly USA, LLC | $23.42 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.69 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $20.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.52 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.16 | 2024 | Edarbi |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.